Immune defects in breast cancer patients after radiotherapy

Journal of the Society for Integrative Oncology

Volumn 6, Issue 3, 2008, Pages 110-121

  Standish, Leanna J ^a   Torkelson, Carolyn ^b   Hamill, Frank A ^a   Yim, Daesong ^a   Hill Force, Alicia ^a   Fitzpatrick, Annette ^a   Olsen, Monica ^a   Schildt, Sandi ^a   Sweet, Erin ^a   Wenner, Cynthia A ^a   Martzen, Mark R ^a  

^a BASTYR UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Breast cancer; Fatigue; Immune defects; Natural killer cell activity; Phagocytic activity; Radiotherapy; Tumor necrosis factor

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; CYCLOPHOSPHAMIDE; CYTOKINE; DOCETAXEL; DOXORUBICIN; ERYTHROPOIETIN; ESTROGEN RECEPTOR; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LETROZOLE; PACLITAXEL; PROGESTERONE RECEPTOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; BLOOD CELL COUNT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOKINE PRODUCTION; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; NATURAL KILLER CELL; NONPARAMETRIC TEST; OUTCOME ASSESSMENT; PHAGOCYTOSIS; POSTOPERATIVE PERIOD; PSYCHOLOGICAL RATING SCALE; RADIATION DOSE; RANK SUM TEST; TREATMENT DURATION;

ADULT; AGED; BLOOD CELL COUNT; BREAST NEOPLASMS; CYTOKINES; FATIGUE; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNE SYSTEM; KILLER CELLS, NATURAL; LYMPHOPENIA; MIDDLE AGED; NEOPLASM STAGING; PHAGOCYTES; RADIOTHERAPY; RISK FACTORS; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 51549103264     PISSN: 1715894X     EISSN: None     Source Type: Journal    
DOI: 10.2310/7200.2008.0018     Document Type: Article

References (27)

1. Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999;80:880-8.
2. Hacene K, Desplaces A, Brunet M, et al. Competitive prognostic value of clinicopathologic and bioimmunologic factors in primary breast cancer. Cancer 1986;57:245-50.
3. Mohanty I, Nayak M, Nanda BK. Cell mediated immune status in carcinoma breast. Indian J Pathol Microbiol 1991;34:1-6.
4. Pross HF, Sterns E, MacGillis DR. Natural killer cell activity in women at "high risk" for breast cancer, with and without benign breast syndrome. Int J Cancer 1984;34:303-8.
5. Claude L, Perol D, Ray-Coquard I, et al. Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 2005;76:334-9.
6. Lowdell MW, Craston R, Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002;117:821-7.
7. Strender LE, Blomgren H, Wasserman J, et al. Influence of adjuvant radiation therapy in breast cancer on PWM induced Ig-secretion by blood lymphocytes in vitro. Anticancer Res 1983;3:41-5.
8. Shukla HS, Hughes LE, Whitehead RH, Newcombe RG. Long-term follow-up of general immune competence in breast cancer. II. Sequential pre- and post-treatment levels: a 10 year study. Cancer Immunol Immunother 1986;21:6-11.
9. Rotstein S, Blomgren H, von Stedingk LV, et al. Long-term effects on the immune system following local irradiation for breast cancer. Pokeweed mitogen induced immunoglobulin secretion by blood lymphocytes and serum immunoglobulin levels. Eur J Surg Oncol 1985;11:137-41.
10. Campbell MJ, Scott J, Maecker HT, et al. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat 2005;91:163-71.
11. Petrini B, Wasserman J, Glas U, Blomgren H. T lymphocyte subpopulations in blood following radiation therapy for breast cancer. Eur J Cancer Clin Oncol 1982;18:921-4.
12. Zielinski CC, Mueller C, Tyl E, et al. Impaired production of tumor necrosis factor in breast cancer. Cancer 1990;66:1944-8.
13. Marucha PT, Crespin TR, Shelby RA, Andersen BL. TNF-alpha levels in cancer patients relate to social variables. Brain Behav Immun 2005;19:521-5.
14. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006;17:325-37.
15. Zielinski CC, Budinsky AC, Wagner TM, et al. Defect of tumour necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriers. Breast Cancer Res Treat 2003;81:99-105.
16. Perik PJ, Van der Graaf WT, De Vries EG, et al. Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. Acta Oncol (Stockh) 2006;45:175-83.
17. Turriziani A, Mattiucci GC, Montoro C, et al. Radiotherapy-related fatigue: incidence and predictive factors. Rays 2005;30:197-203.
18. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003; 97:2919-25.
19. Collado-Hidalgo A, Bower JE, Ganz PA, et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006;12:2759-66.
20. Geinitz H, Zimmermann FB, Stoll P, et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys 2001;51:691-8.
21. Parker R, Berman N. Sample size: more than calculations. Am Statistician 2003;57:166-70.
22. Johann S, Blumel G, Lipp M, Forster R. A versatile flow cytometry-based assay for the determination of short- and long-term natural killer cell activity. J Immunol Methods 1995;185:209-16.
23. Hirai R, Oguchi Y, Sugita N, et al. Enhancement of T-cell proliferation by PSK, Int J Immunopharmacol 1993;15:745-50.
24. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000;5:4-27.
25. Toi M, Hattori T, Akagi M, et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer 1992;70:2475-83.
26. Morimoto T, Ogawa M, Orita K, et al. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Eur J Cancer 1996;32A:235-42.
27. Ashamalla H, Marella V, Feliberti J, et al. Correlation of cytokine levels and response to radiation therapy and/or brachytherapy in low/ intermediate risk prostate cancer. J Clin Oncol 2005;23:13-7.